Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen

The drugmakers will make Praluent available for 60% less than the cholesterol drug's original price, a decision reflective of persistent commercial hurdles.

By Ned Pagliarulo • Feb. 11, 2019

Eylea's PANORAMA data give fuller view of efficacy in label expansion bid

Regeneron's blockbuster eye drug benefited certain patients with severe diabetic retinopathy, a market the big biotech is eager to break into.

By Jacob Bell • Feb. 11, 2019

Explore the Trendline➔

Commercialization

New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

By BioPharma Dive staff

J&J to disclose list prices in TV drug ads

Beginning in March, commercials for J&J's blockbuster blood thinner Xarelto will include list prices — a step beyond PhRMA's planned approach.

By Jacob Bell • Feb. 7, 2019

Mylan takes step toward knocking down key patent for Biogen's top seller

An inter partes review is under way for Tecfidera, though analysts predicted big hurdles remain to a generic of the multiple sclerosis drug.

By Jacob Bell • Feb. 7, 2019

Vertex fears its triplet will also face UK reimbursement battle

U.K. regulators have already been in contentious battles with the biotech over its two-drug regimens for cystic fibrosis.

By Jacob Bell • Feb. 6, 2019

Successful launch bolsters Libtayo's place as cornerstone therapy for Regeneron

The immunotherapy earned $15 million during its first quarter on the market, securing broad access across commercial and government insurance plans.

By Jacob Bell • Feb. 6, 2019

FDA draft lays out submission paths for combo products

Commissioner Scott Gottlieb said the agency will develop additional guidances outlining specific premarket considerations for combo products.

By David Lim • Feb. 6, 2019

Lilly lowers 2019 revenue hopes, citing Lartruvo failure

Lartruvo's clinical failure, pricing pressure and an $8 billion acquisition have caused Lilly to shift business expectations for 2019.

By Andrew Dunn • Feb. 6, 2019

Pharma is shuffling around jobs, but a skills gap threatens the process

Drugmakers have found difficulty luring employees who can work with the latest technologies away from the likes of Amazon and Google, for instance. 

By Jacob Bell • Feb. 4, 2019

In hiking prices, drugmakers show some signs of tempering increases

Analysts at Raymond James found pharma price increases last month to be somewhat smaller than in January 2018 — evidence, perhaps, of some newfound restraint.

By Andrew Dunn • Feb. 4, 2019

Does Merck need more than Keytruda?

The cancer drug's meteoric rise is responsible for most of Merck's growth, but analysts aren't sure if that's such a good thing.

By Jacob Bell • Feb. 1, 2019

Pharma misses its prescription for growth

Sales forecasts for 2019 largely disappointed Wall Street, raising doubts about pharma's ability to sustain the metronomic revenue gains it's regularly enjoyed.

By Ned Pagliarulo • Jan. 31, 2019

J&J's Erleada has big shoes to fill, and a tough competitor to boot

Positive data from the TITAN trial supports a label expansion for the prostate drug, which would be helpful as it competes with Pfizer's Xtandi.

By Jacob Bell • Jan. 31, 2019

Novartis finds stability in Cosentyx amid company shake-ups

The drugmaker expects Cosentyx to grow further, providing a reliable boost as it deals with a large-scale restructuring and generic threats.

By Jacob Bell • Jan. 30, 2019

Anthem accelerates launch of PBM IngenioRx

The insurer now expects earnings to be greater than $19 per share in 2019, company executives said as they issued year-end and fourth quarter results.

By Samantha Liss • Jan. 30, 2019

Amgen's migraine lead faces early test in CVS decision

CVS lists migraine drugs from Teva and Eli Lilly as preferred over Amgen and Novartis' Aimovig, which currently holds an edge in the CGRP market. 

By Ned Pagliarulo • Updated Jan. 30, 2019

Pfizer, Novartis, Amgen add to 2019 drug price hikes

Prices were increased on major products including Novartis' Cosentyx, Pfizer's Xeljanz and Amgen's Enbrel.

By Andrew Dunn • Jan. 25, 2019

Wall Street can't look past AbbVie's Humira problem

Greater-than-expected sales erosion from Humira biosimilars in Europe were a key contributor to AbbVie reporting a rare miss on fourth quarter revenue.

By Jacob Bell • Jan. 25, 2019

Senate Dems again targeting tax deductions for DTC drug ads

While the proposal has been put forward before, the Trump administration's plan to require drugmakers put prices in ads could give fresh momentum for such ideas.

By Jacob Bell • Jan. 23, 2019

Rising insulin prices drive jump in diabetes treatment costs: report

Higher insulin spending accounted for nearly half of a $6,000 jump in per-person spending for Type 1 diabetes care between 2012 and 2016.

By Les Masterson • Jan. 23, 2019

Walgreens pays $270M to settle Medicaid fraud allegations

For years, the U.S. government alleges, the pharmacy giant routinely submitted false data to improperly secure federal reimbursement for insulin pens not needed by patients.

By Suzanne Elvidge • Jan. 23, 2019

FDA approves third biosimilar of Roche's Herceptin

The go-ahead creates yet another threat to one of the Swiss pharma's top-selling franchises.

By Suzanne Elvidge • Jan. 22, 2019

Lilly suspends Lartruvo promotion after Phase 3 failure

A miss on overall survival in the pharma's ANNOUNCE study calls into question the cancer drug's earlier accelerated approval.

By Jacob Bell • Jan. 18, 2019

Sandoz launches EpiPen rival at $250 per two-pack

The much-delayed launch has been a boost for originator Adamis Pharmaceuticals and provides a new competitor to the beleaguered EpiPen.

By Suzanne Elvidge • Jan. 18, 2019

7 biopharma trends to watch in 2019

Intensifying political pressure, surging cancer drug investment and the rise of pharma chief digital officers are among the factors which look set to shape the industry's next 12 months.

By Ned Pagliarulo • Jan. 17, 2019